Abivax S.A.
ABVX
Classement en actions
#2371
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013,... Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
Prix de l'action
$92.14
Capitalisation boursière
$8.04B
Changement (1 jour)
-2.73%
Changement (1 an)
4.27%
Pays
FR
Échange Abivax S.A. (ABVX)
Catégorie
Healthcare
Historique du prix de l'action pour Abivax S.A. (ABVX)
Prix de clôture le plus élevé : $94.68 le 2026-10-01
Prix de clôture le plus bas : $23.10 le 2015-06-01
Prix de clôture le plus bas : $23.10 le 2015-06-01
Historique du prix de l'action de Abivax S.A. de 2015 à 2026
Performance annuelle du prix de l'action
| Année | Performance |
|---|---|
| 2026 (TTM) | -6.04% |
| 2025 | 1,503.20% |
| 2024 | -26.43% |
| 2023 | 60.28% |
| 2022 | -77.75% |
| 2021 | -2.30% |
| 2020 | 54.91% |
| 2019 | 56.94% |
| 2018 | 22.67% |
| 2017 | 47.19% |
| 2016 | -57.07% |
| 2015 | 0.00% |
Prix de l'action pour des entreprises similaires ou concurrentes
| Entreprise | Prix de l'action | Variation 1a% | Pays |
|---|---|---|---|
| $536.74 | 25.87% |
US
|
|
| $227.23 | 746.28% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $881.75 | 8.30% |
NL
|
